Moderna (NASDAQ:MRNA) Stock Update: Cowen & Co. Adjusts Rating to "Hold"

Moderna Inc. (NASDAQ: MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. As the company prepares to release its quarterly earnings on May 1, 2025, Wall Street analysts predict an earnings per share (EPS) of -$2.92. This represents a 4.9% improvement from the previous year, despite a projected revenue decline of 24% to $115.3 million.

The anticipated revenue decline is primarily due to reduced demand for Moderna's COVID-19 vaccine, with expected sales of $112 million. This decrease is significant compared to previous years when the vaccine was in high demand. Additionally, the company's RSV vaccine, mResvia, is expected to contribute minimally to sales, with an estimated $10 million. Investors will be keen to hear updates on Moderna's pipeline during the earnings report.

Over the past month, analysts have slightly adjusted the consensus EPS estimate downward by 0.1%. These revisions are important as they can influence investor reactions and short-term stock price movements. In the previous quarter, Moderna exceeded earnings estimates by 7.06%, but there is concern that the company may not achieve an earnings beat this time. The Zacks Consensus Estimate predicts a quarterly loss of $2.91 per share.

Moderna's financial metrics reveal some challenges. The company has a negative price-to-earnings (P/E) ratio of -3.02, indicating negative earnings. The price-to-sales ratio is about 3.34, suggesting investors are willing to pay $3.34 for every dollar of sales. The enterprise value to sales ratio is approximately 2.96, providing insight into the company's valuation relative to its revenue.

Despite these challenges, Moderna maintains a strong current ratio of about 3.67, indicating a solid ability to cover short-term liabilities with short-term assets. The debt-to-equity ratio is relatively low at 0.065, reflecting a conservative approach to leveraging debt. Investors will closely monitor the earnings call for management's discussion on the sustainability of any immediate price changes and future earnings expectations.

Moderna Inc. (NASDAQ: MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. As the company prepares to release its quarterly earnings on May 1, 2025, Wall Street analysts predict an earnings per share (EPS) of -$2.92. This represents a 4.9% improvement from the previous year, despite a projected revenue decline of 24% to $115.3 million.

The anticipated revenue decline is primarily due to reduced demand for Moderna's COVID-19 vaccine, with expected sales of $112 million. This decrease is significant compared to previous years when the vaccine was in high demand. Additionally, the company's RSV vaccine, mResvia, is expected to contribute minimally to sales, with an estimated $10 million. Investors will be keen to hear updates on Moderna's pipeline during the earnings report.

Over the past month, analysts have slightly adjusted the consensus EPS estimate downward by 0.1%. These revisions are important as they can influence investor reactions and short-term stock price movements. In the previous quarter, Moderna exceeded earnings estimates by 7.06%, but there is concern that the company may not achieve an earnings beat this time. The Zacks Consensus Estimate predicts a quarterly loss of $2.91 per share.

Moderna's financial metrics reveal some challenges. The company has a negative price-to-earnings (P/E) ratio of -3.02, indicating negative earnings. The price-to-sales ratio is about 3.34, suggesting investors are willing to pay $3.34 for every dollar of sales. The enterprise value to sales ratio is approximately 2.96, providing insight into the company's valuation relative to its revenue.

Despite these challenges, Moderna maintains a strong current ratio of about 3.67, indicating a solid ability to cover short-term liabilities with short-term assets. The debt-to-equity ratio is relatively low at 0.065, reflecting a conservative approach to leveraging debt. Investors will closely monitor the earnings call for management's discussion on the sustainability of any immediate price changes and future earnings expectations.

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. The company is navigating a challenging period as it transitions from its COVID-19 vaccine success to introducing new products. Competitors in the biotech sector include Amgen, CRISPR Therapeutics, Sarepta Therapeutics, and Vertex Pharmaceuticals.

Over the past year, Moderna's consensus price target has seen a significant decline. A year ago, analysts set the average price target at $119.26, but it has since dropped to $47.5. This shift indicates a more cautious outlook from analysts, possibly due to market conditions and company performance.

Despite reporting higher-than-expected revenue of $1 billion for the fourth quarter, Moderna faced a GAAP net loss of $1.1 billion. This loss includes $200 million in non-cash charges related to manufacturing resizing. The decrease in demand for its COVID vaccine has impacted the company's financial performance.

Looking forward, Moderna anticipates its 2025 revenue to range between $1.5 billion and $2.5 billion. The company is also working on new products, including a next-generation COVID vaccine, an RSV vaccine, and a flu/COVID combination vaccine. These developments could influence future analyst sentiment.

Deutsche Bank analyst Emmanuel Papadakis has set a price target of $155 for Moderna, reflecting optimism in the company's potential. As Moderna prepares to announce its fourth-quarter earnings, investors are closely watching for updates on its pipeline and any impact on its stock price.

Moderna, Inc. (NASDAQ:MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. The company is navigating a challenging period as it transitions from its COVID-19 vaccine success to introducing new products. Competitors in the biotech sector include Amgen, CRISPR Therapeutics, Sarepta Therapeutics, and Vertex Pharmaceuticals.

Over the past year, Moderna's consensus price target has seen a significant decline. A year ago, analysts set the average price target at $119.26, but it has since dropped to $47.5. This shift indicates a more cautious outlook from analysts, possibly due to market conditions and company performance.

Despite reporting higher-than-expected revenue of $1 billion for the fourth quarter, Moderna faced a GAAP net loss of $1.1 billion. This loss includes $200 million in non-cash charges related to manufacturing resizing. The decrease in demand for its COVID vaccine has impacted the company's financial performance.

Looking forward, Moderna anticipates its 2025 revenue to range between $1.5 billion and $2.5 billion. The company is also working on new products, including a next-generation COVID vaccine, an RSV vaccine, and a flu/COVID combination vaccine. These developments could influence future analyst sentiment.

Deutsche Bank analyst Emmanuel Papadakis has set a price target of $155 for Moderna, reflecting optimism in the company's potential. As Moderna prepares to announce its fourth-quarter earnings, investors are closely watching for updates on its pipeline and any impact on its stock price.

Moderna Inc. (NASDAQ:MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. As the company prepares to release its quarterly earnings on February 14, 2025, analysts are closely watching its financial performance. Moderna's competitors include Pfizer and BioNTech, which also focus on mRNA-based vaccines.

Wall Street analysts estimate Moderna's earnings per share (EPS) to be -$2.86 for the quarter. However, recent projections suggest a slightly better outcome, with an expected loss of $2.65 per share. This marks a significant decline of 581.8% compared to the previous year. Despite this, there has been a 7.2% upward revision in the consensus EPS estimate over the past 30 days, as highlighted by Zacks Investment Research.

Revenue for the quarter is projected to be approximately $941 million, with some estimates slightly higher at $956 million. This represents a 66% decrease from the same quarter last year. A significant portion of Moderna's revenue is expected to come from its COVID-19 vaccine, with sales estimated at $869 million. The decline in revenue is attributed to reduced demand for the vaccine.

Moderna's financial ratios provide insight into its current situation. The company has a negative price-to-earnings (P/E) ratio of -5.29, indicating negative earnings. The price-to-sales ratio is about 2.31, suggesting investors are willing to pay $2.31 for every dollar of sales. Despite negative earnings, Moderna maintains a strong current ratio of 4.39, indicating good short-term financial health.

Investors will be keen to hear updates on Moderna's pipeline during the earnings report. The company's RSV vaccine, mResvia, which received FDA approval in May, is expected to contribute minimally to sales. The management's discussion during the earnings call will be crucial in determining the sustainability of any immediate price changes and future earnings expectations.

Moderna Inc. (NASDAQ:MRNA) is a biotechnology company known for its mRNA technology, which played a crucial role in developing its COVID-19 vaccine. As the company prepares to release its quarterly earnings on February 14, 2025, analysts are closely watching its financial performance. Moderna's competitors include Pfizer and BioNTech, which also focus on mRNA-based vaccines.

Wall Street analysts estimate Moderna's earnings per share (EPS) to be -$2.86 for the quarter. However, recent projections suggest a slightly better outcome, with an expected loss of $2.65 per share. This marks a significant decline of 581.8% compared to the previous year. Despite this, there has been a 7.2% upward revision in the consensus EPS estimate over the past 30 days, as highlighted by Zacks Investment Research.

Revenue for the quarter is projected to be approximately $941 million, with some estimates slightly higher at $956 million. This represents a 66% decrease from the same quarter last year. A significant portion of Moderna's revenue is expected to come from its COVID-19 vaccine, with sales estimated at $869 million. The decline in revenue is attributed to reduced demand for the vaccine.

Moderna's financial ratios provide insight into its current situation. The company has a negative price-to-earnings (P/E) ratio of -5.29, indicating negative earnings. The price-to-sales ratio is about 2.31, suggesting investors are willing to pay $2.31 for every dollar of sales. Despite negative earnings, Moderna maintains a strong current ratio of 4.39, indicating good short-term financial health.

Investors will be keen to hear updates on Moderna's pipeline during the earnings report. The company's RSV vaccine, mResvia, which received FDA approval in May, is expected to contribute minimally to sales. The management's discussion during the earnings call will be crucial in determining the sustainability of any immediate price changes and future earnings expectations.